Last Updated: 02/12/2024

Clinical development of Pfs48/45 as transmission blocking vaccine

Objectives

The objectives of REDMAL are:

1. Manufacture R0-PF10C at cGMP grade

2. Prepare for clinical trials with R0-PF10C in Africa.

Principal Institution

Radboud University Medical Center (Radboudumc), The Netherlands

Principal Investigators / Focal Persons

Robert Sauerwein

Partner Institutions

Statens Serum Institute (SSI), Denmark
London School of Hygiene and Tropical Medicine (LSHTM), United Kingdom
Gennova Biopharmaceuticals, India
Kilimanjaro Christian Medical University College (KCMUCo), Tanzania
African Malaria Network Trust (AMANET), Tanzania

Rationale and Abstract

Pfs48/45 is the most advanced EU-developed malaria TB vaccine candidate. PF10C is a subunit of Pfs48/45 that has been produced as R0-PF10C. Immunization with 100% properly folded R0-PF10C induced transmission-blocking activity in 100% of immunized mice. Malaria vaccines are needed to reduce the unacceptably high burden of disease and death in particular in the lowest income countries. Malaria vaccines aim at interruption of the life cycle of the parasite Plasmodium falciparum by induced immune responses in the humans. Transmission-blocking vaccines (TBMV) specifically aim at an arrest sexual stage development preventing the generation of infectious mosquitoes. TBMVs are the most effective tools for reduction of the spread of malaria in the population. This is indispensible for sustained control, elimination and eventually eradication. Pfs48/45 is the most advanced EU-developed malaria TBMV candidate. PF10C is a subunit of Pfs48/45 that has been produced as R0-PF10C in a 20L fermentor. Immunization with 100% properly folded R0-PF10C induced transmission-blocking activity in 100% of immunized mice.

External reference

Project details

Themes

Vaccines

Date

Mar 2010 — Nov 2014

Total Project Funding

$6.24M

Funding Details

Seventh Framework Programme of the European Union (FP7), Belgium

Grant ID: 242079

EUR 4.58M